Needle-phobic? FluMist nasal spray vaccine available for use at home
That's why some doctors are hoping that the first nasal flu vaccine available for use at home can improve vaccination rates among people, especially children, who are afraid of needles.
AstraZeneca's FluMist Home, which was approved last fall, is now available with a prescription for children ages 2 and over, and adults up to age 49.
A 2019 review from researchers at the University of Michigan found the majority of children and up to 30% of young adults are afraid of needles.
Dr. Zachary Hoy, board-certified pediatric infectious disease specialist at Pediatrix Medical Group in Nashville, Tennessee, said many children are scared because they aren't old enough to understand what vaccines are and why they are important.
'Most of the time, the anxiety and worry before the shot is scarier than the actual shot,' Hoy said.
How does FluMist Home work?
The vaccine was first approved in 2003 to be given in a doctor's office. However, after the 2009 swine flu pandemic introduced the new H1N1 strain, several studies found the nasal spray was less effective than other flu vaccines. This prompted the Centers for Disease Control and Prevention to recommend against using the nasal spray in 2016. At the time, the CDC said the nasal spray accounted for one-third of all flu vaccines given to children.
In response, FluMist's manufacturers reformulated it to more closely match circulating strains, including H1N1, and the nasal spray returned in 2018. Like injectable flu vaccines, FluMist is updated each season based on recommendations from global health officials.
'FluMist's efficacy is comparable to injectable flu vaccines and is a safe and effective needle-free option for flu protection,' AstraZeneca spokesperson Andrew Leone said.
Experts say it's too early to tell how bad the upcoming flu season will be.
Typically, flu vaccines are 40% and 60% effective in preventing severe illness, and FluMist Home should be equally protective. The doses for the 2026-2027 season contain three virus strains: an A/H1N1 strain, an A/H3N2 strain and a B strain from the B/Victoria lineage, according to the drugmaker.
The FluMist Home vaccine contains a weakened form of a live virus to stimulate the immune system. Pregnant women or people with compromised immune systems are advised to talk with their doctor before using it.
Does insurance cover it?
FluMist Home is available only online. People ordering the nasal spray will need to complete a medical screening questionnaire at FluMist.com that is reviewed by a health care professional, according to the drugmaker. FluMist Home's online pharmacy will then collect the insurance information and bill the health plan directly.
A temperature monitor on the packaging will verify that the vaccine has been maintained at the appropriate temperature during shipping and delivery. Green means it's safe to use. Red means it's not.
Christina Aungst, senior pharmacy editor at GoodRx, estimates people with insurance will likely only have to pay an $8.99 shipping fee for the nasal spray.
'Currently, if you don't have insurance, FluMist is only available in a health care setting,' AstraZeneca's Leone said. 'We hope to provide a cash pay option for FluMist Home in future seasons.'
When FluMist is given in a health care office or clinic, most insurance plans — including Medicare and Medicaid — will cover it.
Dr. Scott Roberts, associate medical director of infection prevention at Yale School of Medicine, worries people may not administer the nasal spray vaccine properly without a doctor's supervision.
'What if they have a runny nose? How far back do they need to spray in the nose? What if they store it incorrectly in their house?' Roberts asked.
Dr. Kristina Bryant, pediatric infectious diseases physician at Norton Children's in Louisville, Kentucky, and a member of the American Academy of Pediatrics Committee on Infectious Diseases, said the bottom line is that all the available flu vaccines offer comparable protection.
'The most important thing to know is that vaccines only work if they are actually administered,' Bryant said. 'Hopefully, the availability of a vaccine that can be administered in the home will make it easier for some people to be protected against flu.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
23 minutes ago
- Newsweek
No Time for the Doctor? You Can Give Yourself a Flu Vaccine
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. AstraZeneca's FluMist nasal spray, which was first approved by the U.S. Food and Drug Administration (FDA) in 2003, is now available through prescription for at-home use, a statement issued by the company said Friday. Newsweek has reached out to the American Medical Association (AMA) for comment on the vaccine on Saturday. Why It Matters While it's not a new vaccine, FluMist Home nasal spray widens the availability to those who may not previously had access. The at-home option also removes the need for a doctor to administer the vaccine, which public health experts say could increase vaccination uptake by addressing convenience and needle-avoidance barriers. This comes ahead of the 2025-26 influenza season in hopes to prevent the unusually high caseload seen the previous season. What To Know FluMist Home uses the same live attenuated intranasal formulation that is available in clinical settings like doctors' offices. The product is approved for children as young as 2 years old and up to adults aged 49. People who are pregnant, immunocompromised, and minors who take aspirin are advised not to take the vaccine, according to the company. Based on data from October 1, 2024, through May 17, 2025, the U.S. Centers for Disease Control and Prevention (CDC) estimated that there were up to 82 million flu related cases, 37 million medical visits, 1.3 million hospitalizations and 130,000 deaths across the U.S. during the 2024-25 flu season. The CDC says the best way to prevent the flu is to get a vaccine, however it's not available to everyone. Only 34 states, about 80 percent of the eligible population, have the option for the at-home vaccine, according to AstraZeneca's Friday statement. "There are a number of states where FluMist Home is unavailable due to local pharmacy laws," the statement said. "Our aim is to have this service available in all 48 contiguous states in future seasons." People over the age of 18 can go online, fill out a medical questionnaire and have the vaccine sent to them for self-administration. A sign telling customers that they can get a flu shot in a Walgreens store is seen on September 16, 2014, in Indianapolis. A sign telling customers that they can get a flu shot in a Walgreens store is seen on September 16, 2014, in Indianapolis. AP Photo/Darron Cummings, File What People Are Saying Joris Silon, US Country President and Senior Vice President, AstraZeneca, said in the statement issued Friday: "The launch of FluMist Home is a transformational moment in the evolution of influenza protection, bringing a simple and accessible option directly into the hands of consumers. FluMist Home reflects the growing importance of direct-to-consumer offerings and underscores our commitment to continuous innovation, making it easier for people to get vaccinated and stay protected." Dr. Peter Hotez, co-director of the Center for Vaccine Development at Texas Children's Hospital, told CNN Friday: "We learned during COVID how home diagnostic testing became widely accepted and that turned out to be a great public health intervention. Given the low uptake of seasonal flu vaccine in America, I think it is worth exploring some novel approaches." What Happens Next? It is unclear how many people will order the vaccine, but the outcomes of availability will be monitored by public health officials to see if the number of vaccinated patients, the number of cases, and even deaths change amid the newly available home vaccine. AstraZeneca urges users to report any side effects from taking the FluMist Home.
Yahoo
an hour ago
- Yahoo
AstraZeneca (LSE:AZN) Launches FluMist Home For At-Home Influenza Vaccination
AstraZeneca recently launched "FluMist Home," an at-home flu vaccine delivery service, marking an important milestone for easier access to vaccinations in 34 U.S. states. This initiative likely contributed to its stock price increase of 12% last quarter, as it aligns with AstraZeneca's push towards innovative healthcare solutions. Despite this positive development, the overall market also experienced an upward trend, with the Dow hitting record highs and the market up 1% over the last week. AstraZeneca's performance seems to have been buoyed by both its strategic product launches and the broader market gains. Every company has risks, and we've spotted 2 possible red flags for AstraZeneca you should know about. The end of cancer? These 26 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's. The launch of AstraZeneca's "FluMist Home" aligns well with the company's focus on innovative healthcare solutions, potentially impacting the narrative around its future growth. This new service might enhance revenue streams by tapping into the demand for convenient medical solutions. Over the last five years, AstraZeneca's total shareholder returns, including both share price and dividends, have risen by 54.08%. This growth provides a broader context to the company's performance, indicating resilience and strong returns for investors. Over the past year, AstraZeneca's share price movement has been in line with the performance of the UK Pharmaceuticals industry, which returned 10.3%. Looking at the potential impact on revenue and earnings forecasts, the initiative could bolster AstraZeneca's earnings as analysts anticipate a growth to $13.9 billion by 2028, up from $8.3 billion today. The recent stock price increase narrows the gap to the consensus analyst price target of £137.89, reflecting a potential 18.95% discount from the current share price of £115.92. This price movement suggests optimism among investors regarding the company's ability to meet future expectations. Our comprehensive valuation report raises the possibility that AstraZeneca is priced lower than what may be justified by its financials. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include LSE:AZN. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
7 hours ago
- Yahoo
Deadly trend on the rise in major state
Victoria has been rocked by the highest number of fatal overdoses in a decade, with nearly 600 residents dying from drug overdoses last year alone. Ten years ago, illicit drugs contributed to less than half of all overdose deaths. In 2024, the Coroners Court found this figure increased to 65.6 per cent. It's a figure increasing yearly, with 584 Victorian residents dying from drug overdoses in 2024, up from 547 the year before and 552 in 2022. Heroin contributed to 248 deaths in the state, and 215 deaths were related to methamphetamine – a stat that has tripled since 2015. The majority of all overdose deaths occurred in metropolitan Melbourne, with about 75 per cent being unintentional. Monash University Associate Professor Shalini Arunogiri told NewsWire the bleak new figures were a reminder of the lack of treatment available for opioid addictions. 'Each of these 584 deaths represents a life lost unnecessarily,' she said. 'Behind every statistic is someone's loved one, a friend, a sibling, a parent.' Worryingly, the majority of the fatal overdoses were men, who made up two-thirds of total deaths over the past decade. Ms Arunogiri said there was a 'strong connection' between drug abuse and mental health, especially if people lacked access to mental health support and effective treatment and instead turned to substances as their 'only available relief'. 'People often turn to substances as a way of coping with untreated trauma, anxiety, depression or other psychological distress,' she said. 'This is why integrated care that treats both mental health and substance use is so important.' The increase in fatal heroin and methamphetamine overdoses was 'particularly concerning', Ms Arunogiri said, as harm reduction methods were available to prevent further deaths. 'The positive here is that solutions do exist, we just need to implement what works,' she said. 'Expanding medication-assisted treatment for opioid addiction must be a priority, given heroin's role as the top contributor.' Ms Arunogiri said lifesaving medications needed to be provided at a faster rate to prevent overdoses. 'Medications like methadone and buprenorphine can reduce the risk of overdose, but people often face long waits for care,' she said. 'Effective measures like drug checking and expanding access to opioid overdose reversal medications, such as naloxone, is also critical.' Penington Institute chief executive John Ryan said 'too many Australians are dying from preventable drug overdoses' and argued governments were '(refusing) to fully embrace measures to drive down this horrific toll'. 'We're still not spending enough money on proven harm reduction initiatives like drug testing, supervised injecting, community education and the wide provision of the anti-overdose drug naloxone,' he said. In May, the Victorian government introduced its take-home naloxone program, which was expanded across 50 needle and syringe program providers, including over the counter at pharmacies, at the Medically Supervised Injecting Room and via prescription to expand access to the medication. Make an appointment with a GP or a mental health professional or get in touch with a drug support service. ReachOut: to learn more about drug and alcohol addiction, for peer support and for pathways to other support services. Alcohol and Drug Foundation: or phone 1300 85 85 84 DirectLine: confidential drug and alcohol telephone counselling, information and referral, 1800 888 236 Self Help Addiction Resource Centre (SHARC): 1300 660 068 For support for people concerned about a relative or friend using drugs Kids Helpline (24 hours a day, 7 days a week): confidential and private counselling service for children and young people (5-25 years). 1800 55 1800 Youth Support and Advocacy Service (YSAS): for people aged between 12-21 who are experiencing problems related to alcohol and other drugs. 1800 458 685 Headspace: Ms Arunogiri said these were 'important steps' to preventing further harm. 'These evidence-based interventions are crucial, but we need further investment to make sure everyone can access the health care they need,' she said. 'The most devastating thing is that we know these deaths were preventable. 'We understand what works – effective medications, harm reduction services, early intervention, but we need to remove the barriers that keep people from accessing the healthcare we all deserve.'
